ArticleInternational ophthalmology2025
SIGLEC1 ubiquitination and degradation induced by MARCHF3 protects ARPE19 retinal cells from high glucose-induced oxidative stress, inflammation, and apoptosis.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alpinia Oxyphylla-Shenqi Siwu Decoction protects against high glucose-induced retinal pigment epithelial cell injury involving the PI3K/AKT/mTOR pathway.International ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the onset of diabetic retinopathy (DR), hyperglycemia enhances oxidative stress, and excessive inflammation drives retinal disturbance. SIGLEC1 is a surface adhesion molecule that participates in immunoregulation and inflammation. This study investigated the functions and related mechanisms of SIGLEC1 in affecting high glucose (HG)-triggered retinal inflammation and oxidative stress.
methodsARPE19 retinal cells were exposed to HG conditions. mRNA expression was analyzed by quantitative PCR, and protein analysis was performed by immunoblotting. Changes in cellular inflammation and oxidative stress were evaluated by measuring related markers. The MARCHF3/SIGLEC1 interaction and SIGLEC1 ubiquitination were detected by co-immunoprecipitation (Co-IP) assay. Treatment of cycloheximide (CHX) was used to analyze SIGLEC1 protein stability.
resultsThe GSE221521 dataset showed that SIGLEC1 was upregulated and MARCHF3 was downregulated in blood samples of DR patients. The consistent expression patterns were also found in HG-stimulated ARPE19 cells. Functionally, SIGLEC1 depletion attenuated HG-triggered inflammation, oxidative stress and apoptosis in ARPE19 cells. Conversely, MARCHF3 downregulation exacerbated HG-triggered inflammation and oxidative stress in ARPE19 cells. Mechanistically, MARCHF3 was confirmed as a key ubiquitin ligase regulating SIGLEC1 protein stability through ubiquitination and degradation. SIGLEC1 restoration partially abolished MARCHF3-caused anti-oxidative stress and anti-inflammation effects in HG-stimulated ARPE19 cells. Additionally, MARCHF3 inactivated HG-induced NF-κB activation via downregulation of SIGLEC1 in ARPE19 cells.
conclusionOur findings suggest that SIGLEC1 ubiquitination and degradation induced by MARCHF3 protects ARPE19 cells from HG-triggered inflammation and oxidative damage.
Indexed as
Identifiers
40682693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.